UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants

Timmers, M; Barão, S; Van Broeck, B; Tesseur, I; Slemmon, J; De Waepenaert, K; Bogert, J; ... Streffer, JR; + view all (2017) BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. Journal of Alzheimer's Disease , 56 (4) pp. 1437-1449. 10.3233/JAD-160829. Green open access

[thumbnail of jad-prepress%2Fjad--1--1-jad160829%2Fjad--1-jad160829.pdf]
Preview
Text
jad-prepress%2Fjad--1--1-jad160829%2Fjad--1-jad160829.pdf - Accepted Version

Download (1MB) | Preview

Abstract

The β-site amyloid-β protein precursor (AβPP) cleaving enzyme-1 (BACE1) is the rate limiting enzyme in the generation of amyloid-β peptide (Aβ) from AβPP, one of the major pathways in Alzheimer's disease (AD) pathology. Increased BACE1 levels and activity have been reported in the brain of patients with sporadic AD. Therefore, changes of BACE1 levels in the cerebrospinal fluid (CSF) have also been investigated as a possible biomarker of the disease. We analyzed BACE1 levels in CSF of elderly healthy participants before and after chronic treatment with a BACE inhibitor (BACEi) and evaluated the correlation between BACE1 levels and downstream AD markers. Overall, BACE1 CSF levels showed strong correlations to all downstream AD markers investigated. This is the first reported finding that shows BACE1 levels in CSF were well correlated to its end product Aβ1 - 42. As previously described, BACE1 levels were strongly correlated to total-tau and phosphorylated tau levels in CSF. Generally, chronic BACE inhibition did not influence BACE1 CSF protein levels. Follow-up studies including early-stage AD pathophysiology and prodromal AD patients will help to understand the importance of measuring BACE1 routinely in daily clinical practice and AD clinical trials.

Type: Article
Title: BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants
Location: Netherlands
Open access status: An open access version is available from UCL Discovery
DOI: 10.3233/JAD-160829
Publisher version: http://dx.doi.org/10.3233/JAD-160829
Additional information: © 2017 – IOS Press and the authors. This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0)
Keywords: AD markers, Alzheimer’s disease, BACE-1, JNJ-54861911, β-secretase enzyme
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UK Dementia Research Institute HQ
URI: https://discovery-pp.ucl.ac.uk/id/eprint/1541065
Downloads since deposit
4,256Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item